Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.59 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.59 |
| ▸ | MAPT | P10636 | 5/20 | 0.50 |
| ▸ | MEN1 | O00255 | 4/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | RAB9A | P51151 | 3/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | CASP3 | P42574 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7542217 | 1.00 | ALDH1A1 (0.59) | ALDH1A1CYP2A6MAPTMEN1KMT2A | |
| SCHEMBL5469857 | 0.90 | CYP2A6 (0.50) | ALDH1A1CYP2A6MAPTMEN1KMT2A | |
| SCHEMBL3074403 | 0.90 | CYP2A6 (0.50) | ALDH1A1CYP2A6MAPTMEN1KMT2A | |
| SCHEMBL9640411 | 0.82 | ALDH1A1 (0.52) | ALDH1A1CYP2A6MAPTMEN1KMT2A | |
| SCHEMBL9640413 | 0.82 | ALDH1A1 (0.52) | ALDH1A1CYP2A6MAPTMEN1KMT2A | |
| SCHEMBL2316309 | 0.80 | ALDH1A1 (0.52) | ALDH1A1CYP2A6MAPTMEN1KMT2A | |
| SCHEMBL15355549 | 0.80 | ALDH1A1 (0.63) | ALDH1A1MAPTMEN1KMT2ARAB9A | |
| SCHEMBL13451257 | 0.80 | ALDH1A1 (0.63) | ALDH1A1MAPTMEN1KMT2ARAB9A | |
| SCHEMBL15132514 | 0.79 | ALDH5A1 (0.73) | ALDH1A1MAPTMEN1KMT2ARAB9A | |
| SCHEMBL28987870 | 0.79 | PTGS1 (0.44) | ALDH1A1CYP2A6MAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 102 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115038790-B | Synthesis of 3' -RNA oligonucleotides | 阿尔尼拉姆医药品有限公司 | 2024-06-21 | — | — | CN | claimed |
| WO-2023064530-A1 | EXTRA-HEPATIC DELIVERY IRNA COMPOSITIONS AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2023-04-20 | — | — | WO | claimed |
| CN-115038790-A | Synthesis of 3' -RNA oligonucleotides | 阿尔尼拉姆医药品有限公司 | 2022-09-09 | — | — | CN | claimed |
| US-20110201528-A1 | Methods Of Forming An Oligomer Array | KUMHO PETROCHEMICAL CO., LTD. (KP) | 2011-08-18 | — | — | US | claimed |
| US-7622248-B2 | Ribozymes with broad tRNA aminoacylation activity | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2009-11-24 | — | — | US | claimed |
| US-7271258-B2 | Methods of synthesizing oligonucleotides using carbonate protecting groups and alpha-effect nucleophile deprotection | AGILENT TECHNOLOGIES, INC. (US) | 2007-09-18 | — | — | US | claimed |
| US-20060252924-A1 | Methods of synthesizing oligonucleotides using carbonate protecting groups and alpha-effect nucleophile deprotection | THE REGENTS OF THE UNIVERSITY OF COLORADO | 2006-11-09 | — | — | US | claimed |
| EP-1483282-A1 | RIBOZYMES WITH BROAD tRNA AMINOACYLATION ACTIVITY | The Research Foundation of State University of New York (US) | 2004-12-08 | — | — | EP | claimed |
| US-20030228593-A1 | Ribozymes with broad tRNA aminoacylation activity | RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK, THE | 2003-12-11 | — | — | US | claimed |
| US-6630581-B2 | Condensing the 3'-OH or 5'-OH group of a support-bound nucleoside or oligonucleotide with a monomeric nucleoside phosphoramidite having a carbonate-protected hydroxyl group; treating the intermediate provided with a deprotecting reagent | AGILENT TECHNOLOGIES, INC. | 2003-10-07 | — | — | US | claimed |
| WO-2003070740-A1 | RIBOZYMES WITH BROAD tRNA AMINOACYLATION ACTIVITY | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2003-08-28 | — | — | WO | claimed |
| US-20020045221-A1 | Solid phase synthesis of oligonucleotides using carbonate protecting groups and alpha-effect nucleophile deprotection | THE REGENTS OF THE UNIVERSITY OF COLORADO | 2002-04-18 | — | — | US | claimed |
| US-6222030-B1 | CONDENSING HYDROXY GROUP OF BOUND OLIGONUCLEOTIDE OR NUCLEOSIDE WITH NUCLEOSIDE PHOSPHORAMIDITE HAVING CARBONATE-PROTECTED HYDROXYL GROUP, TREATING WITH DEPROTECTING AGENT ALSO OXIDIZES PHOSPHITE TRIESTER LINKAGE | AGILENT TECHNOLOGIES, INC. | 2001-04-24 | — | — | US | claimed |
| US-4176009-A | HYDROLYZING OLIGOPEPTIDES IN A AQUEOUS SOLUTION TO RELEASE PEPTIDE FRAGMENTS, USING COLORIMETRIC ANALYSIS AFTER SOLVENT EXTRACTION | AJINOMOTO CO., INC. (JP) | 1979-11-27 | — | — | US | claimed |
| US-4138394-A | Peptide derivatives and a method of measuring collagenase activity | AJINOMOTO CO., INC. (JP) | 1979-02-06 | — | — | US | claimed |
| JP-53028165-A | — | — | None | — | — | JP | disclosed |
| CN-115038790-B | Synthesis of 3' -RNA oligonucleotides | 阿尔尼拉姆医药品有限公司 | 2024-06-21 | — | — | CN | disclosed |
| US-3956269-A | POLYMERIZATION CATALYSTS | PENNWALT CORPORATION (US) | 1976-05-11 | — | — | US | disclosed |
| US-3954475-A | Photosensitive elements containing chromophore-substituted vinyl-halomethyl-s-triazines | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1976-05-04 | — | — | US | disclosed |
| JP-S05328165-A | — | — | 0001-01-01 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060252924-A1 | Methods of synthesizing oligonucleotides using carbonate protecting groups and alpha-effect nucleophile deprotection | POLL, DNTT, RNGTT | ALDH1A1 2559/4885CYP2A6 3959/4885MAPT 3581/4885 |
| US-20020045221-A1 | Solid phase synthesis of oligonucleotides using carbonate protecting groups and alpha-effect nucleophile deprotection | POLL, RNGTT, DNTT | ALDH1A1 2882/4885CYP2A6 3487/4885MAPT 3855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.